regulatory
confidence high
sentiment negative
materiality 0.65
Outlook Therapeutics receives Nasdaq notice for bid price below $1.00, has until March 24, 2027 to regain compliance
Outlook Therapeutics, Inc.
- Nasdaq notified Outlook Therapeutics on Sept 25, 2026 that its closing bid price was below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
- The company has 180 calendar days, until March 24, 2027, to regain compliance, requiring a closing bid price of at least $1.00 for 10 consecutive business days.
- Outlook may qualify for an additional 180-day period and could effect a reverse stock split to cure the deficiency.
- If not cured by the Compliance Date, Nasdaq will notify of delisting; the company may appeal to a hearings panel, but success is not assured.
- CFO Kevin Lundquist signed the Form 8-K dated September 30, 2026.